Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Immunocore Holdings plc
  6. News
  7. Summary
    IMCR   US45258D1054

IMMUNOCORE HOLDINGS PLC

(IMCR)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Health Care Stocks Putting Up Modest Gains

01/26/2022 | 01:28pm EDT
share with twitter
share with LinkedIn
share with facebook


© MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
AUSTRALIAN DOLLAR / US DOLLAR (AUD/USD) -0.13% 0.7032 Delayed Quote.-3.01%
BRITISH POUND / US DOLLAR (GBP/USD) 0.19% 1.24866 Delayed Quote.-7.89%
CANADIAN DOLLAR / US DOLLAR (CAD/USD) -0.17% 0.7783 Delayed Quote.-1.43%
EURO / US DOLLAR (EUR/USD) -0.11% 1.0548 Delayed Quote.-6.97%
HEPION PHARMACEUTICALS, INC. 0.11% 0.7458 Delayed Quote.-34.58%
IMMUNOCORE HOLDINGS PLC 3.99% 30.21 Delayed Quote.-11.77%
INDIAN RUPEE / US DOLLAR (INR/USD) -0.59% 0.012844 Delayed Quote.-3.79%
NASDAQ COMP. -0.30% 11354.62 Real-time Quote.-27.42%
NEW ZEALAND DOLLAR / US DOLLAR (NZD/USD) 0.38% 0.64048 Delayed Quote.-6.67%
TYME TECHNOLOGIES, INC. 0.66% 0.274 Delayed Quote.-54.57%
All news about IMMUNOCORE HOLDINGS PLC
05/11Immunocore Holdings Q1 Net Loss Narrows as Revenue Rises
MT
05/11Immunocore Holdings plc Reports Earnings Results for the First Quarter Ended March 31, ..
CI
05/11Immunocore Reports First Quarter 2022 Financial Results and Provides Business Update
GL
04/18IMMUNOCORE : Corporate Presentation - April 2022
PU
04/07Immunocore to present at the 21st Annual Needham Healthcare Conference
AQ
04/04IMMUNOCORE : European Commission Approves KIMMTRAK® (tebentafusp) for the treatment of unr..
PU
04/04Immunocore Wins European Regulatory Ok of Kimmtrak for Unresectable or Metastatic Uveal..
MT
04/04European Commission Approves KIMMTRAK® (tebentafusp) for the treatment of unresectable ..
GL
04/04European Commission Approves KIMMTRAK® (tebentafusp) for the treatment of unresectable ..
GL
04/04European Commission Approves Immunocore Holdings plc's KIMMTRAK (Tebentafusp) for the T..
CI
More news
Analyst Recommendations on IMMUNOCORE HOLDINGS PLC
More recommendations
Financials
Sales 2022 83,5 M 104 M 104 M
Net income 2022 -89,2 M -111 M -111 M
Net cash 2022 226 M 282 M 282 M
P/E ratio 2022 -12,3x
Yield 2022 -
Capitalization 1 064 M 1 326 M 1 326 M
EV / Sales 2022 10,0x
EV / Sales 2023 11,3x
Nbr of Employees 324
Free-Float 37,6%
Chart IMMUNOCORE HOLDINGS PLC
Duration : Period :
Immunocore Holdings plc Technical Analysis Chart | IMCR | US45258D1054 | MarketScreener
Technical analysis trends IMMUNOCORE HOLDINGS PLC
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Last Close Price 2 423,60 GBX
Average target price 4 291,74 GBX
Spread / Average Target 77,1%
EPS Revisions
Managers and Directors
Bahija Jallal Chief Executive Officer & Director
Brian R. DiDonato Chief Financial Officer & Head-Strategy
John Irving Bell Chairman
David Berman Head-Research & Development
Travis Coy Independent Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
IMMUNOCORE HOLDINGS PLC-11.77%1 326
MODERNA, INC.-46.35%54 195
LONZA GROUP AG-27.84%41 796
IQVIA HOLDINGS INC.-28.46%38 202
SEAGEN INC.-9.68%25 704
ICON PUBLIC LIMITED COMPANY-30.22%17 567